When will mobosetinib/mobosetinib be officially included in medical insurance?

Mobocertinib is a targeted anti-cancer drug targeting EGFR mutations and is mainly used to treat specific types of non-small cell lung cancer. The drug has received widespread attention internationally and has brought new hope to patients with refractory lung cancer. However, for some reason, the original drug of moboxetinib has been removed from the market in China, which makes it extremely difficult to obtain the drug.

At present, there is still unclear information on when moboxetinib will be officially included in medical insurance. Under normal circumstances, drugs that can be included in the medical insurance catalog need to undergo strict review and evaluation, including comprehensive consideration of clinical effectiveness, safety, economics and other factors. Although moboxetinib has achieved certain therapeutic effects internationally, factors such as its price, accessibility, and market demand will also affect its inclusion in medical insurance.

As the country attaches great importance to anti-cancer drugs, many new drugs have been included in the medical insurance catalog in recent years, thereby reducing the financial burden on patients. However, the medical insurance status of moboxetinib is still unresolved, causing trouble to the majority of patients. Due to the removal of the drug from the shelves, patients cannot legally obtain the drug through domestic hospitals or pharmacies, which undoubtedly increases patients' anxiety and financial pressure during the treatment process.

In such cases, some patients may choose to seek other ways to obtain the drug. For example, some patients may consider purchasing through overseas channels. However, this approach is often accompanied by high costs and legal risks. At the same time, patients also need to carefully screen the source of the drugs they purchase to ensure their quality and safety.

In addition to purchasing the drug at their own expense, patients and their families can also obtain more latest developments and information about moboxetinib by participating in patient organizations. These organizations can often provide support and counseling to help patients understand how to cope with their current medication dilemma.

Reference materials:https://en.wikipedia.org/wiki/Mobocertinib